Sean Mulqueeny, OD
Optometrist · Creve Coeur, MONPI 1407871296
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,521 of the $44,775 with a category attached, or 61.5%. AbbVie accounts for 67.9% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2022 at $16,745 and has fallen 94.1% since, to $993 in 2025. Among optometrist clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 328 payments — averaging $136.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$30K
- Shire North American Group Inc$5K
- Alcon$5K
- Oyster Point Pharma, Inc.$1K
- Novartis$620
- Bausch & Lomb Americas Inc.$509
- plus $3K from 17 others
What the payments were for
- Consulting fees$5,18012%
- Speaking & faculty fees$27,52161%
- Travel & lodging$3,6428%
- Food & beverage$8,43219%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 109 | $30,415 |
| Shire North American Group Inc | 15 | $4,788 |
| Alcon | 33 | $4,629 |
| Oyster Point Pharma, Inc. | 21 | $1,068 |
| Novartis | 13 | $620 |
| Bausch & Lomb Americas Inc. | 26 | $509 |
| Coopervision Inc. | 10 | $457 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 25 | $398 |
| Johnson & Johnson Vision Care, Inc. | 9 | $300 |
| Sun Pharmaceutical Industries Inc. | 12 | $265 |
| Amgen(2 entities) | 3 | $248 |
| Tarsus Pharmaceuticals, Inc. | 10 | $242 |
| Glaukos Corporation | 5 | $184 |
| Kala Pharmaceuticals, Inc. | 9 | $175 |
| Eyevance Pharmaceuticals LLC | 7 | $117 |
| Dompe US, Inc. | 4 | $84 |
| Harrow Eye, LLC | 3 | $71 |
| Sight Sciences, Inc. | 3 | $58 |
| Biotissue Holdings Inc. | 6 | $42 |
| LKC Technologies, Inc. | 2 | $34 |
| Synergeyes, Inc. | 1 | $27 |
| Aerie Pharmaceuticals, Inc. | 1 | $21 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VUITY$15,348
- RESTASIS$8,811
- XIIDRA$4,903
- DAILIES TOTAL1$3,588
- RESTASIS MULTIDOSE$2,169
- TYRVAYA$616
- TEPEZZA$225
- MyDay Contact Lens$170
- Acuvue$146
- TOTAL30$144
- Precision 1$127
- INFUSE$125
- DURYSTA$112
- MiSight Contact Lens$107
- TRYPTYR$105
How this compares
$44,775 in reported general payments places this provider in the 95th percentile of 1,030 optometrist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 26 | $32,940 |
| MieboPerfluorohexyloctane/Pf | 11 | $8,317 |
| LumiganBimatoprost | 17 | $7,823 |
| VyzultaLatanoprostene Bunod | 11 | $3,954 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 14 | $2,890 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $2,656 |
| Brimonidine Tartrate | 32 | $1,220 |
| Prednisolone Acetate | 31 | $906 |
| Latanoprost | 46 | $477 |
| Ketorolac Tromethamine | 13 | $347 |
| Doxycycline Hyclate | 17 | $211 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 20 | $146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $30,415 | $43,41856 claims |
| Bausch & Lomb Americas Inc.Miebo, Vyzulta | $509 | $12,27122 claims |
| AlconSimbrinza | $4,629 | $2,89014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,030 optometrist providers in Missouri.
Other optometrist in Creve Coeur
- Todd BellamyCreve Coeur$12K
- George DowdyCreve Coeur$6K
- Andrew BiondoKirkwood$300K
- John McGrealSaint Louis$126K
- Alana KellerWildwood$94K
- Sarah HubbardChesterfield$91K
- Ariel CerenzieSaint Louis$76K
- Geoffrey PowellKansas City$55K
- Thomas HobbsSedalia$53K
- Heather WebsterColumbia$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.